Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22630335 | 0.85 | HSD17B10 (0.50) | TARBP2PPARANPC1RAB9ATSHR | |
| SCHEMBL2980371 | 0.84 | KDM4E (0.59) | PPARGPPARANPC1RAB9AKDM4E | |
| SCHEMBL5103005 | 0.83 | RXFP1 (0.49) | PPARGPPARANPC1RAB9ATSHR | |
| SCHEMBL9096448 | 0.82 | ALDH1A1 (0.50) | TARBP2NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL5759578 | 0.81 | KDM4E (0.47) | PPARGPPARARAB9AKDM4EALDH1A1 | |
| SCHEMBL3996100 | 0.80 | TARBP2 (0.50) | TARBP2PPARGPPARANPC1RAB9A | |
| SCHEMBL14431360 | 0.80 | TARBP2 (0.50) | TARBP2PPARGPPARANPC1RAB9A | |
| SCHEMBL5023940 | 0.80 | TARBP2 (0.50) | TARBP2PPARGPPARANPC1RAB9A | |
| SCHEMBL5093853 | 0.80 | TARBP2 (0.54) | TARBP2PPARGPPARANPC1RAB9A | |
| SCHEMBL4830096 | 0.80 | TARBP2 (0.50) | TARBP2PPARGPPARANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | BROOKS DAWN ALISA | 2008-06-19 | — | — | US | disclosed |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | BROOKS DAWN ALISA | 2008-06-19 | — | — | US | disclosed |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | BROOKS DAWN ALISA | 2008-06-19 | — | — | US | disclosed |
| US-7351728-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351728-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351728-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1313715-B1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-6982278-B2 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050250825-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | BROOKS DAWN A | 2005-11-10 | — | — | US | disclosed |
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
| US-20040024034-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | BROOKS DAWN ALISA (US) | 2004-02-05 | — | — | US | disclosed |
| EP-1313717-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1313715-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2002018355-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002016332-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250825-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists | PPARA, PPARG, PPARD | TARBP2 4491/4885PPARG 2/4885PPARA 1/4885 |
| US-20040024034-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | PPARA, PPARG, PPARD | TARBP2 4537/4885PPARG 2/4885PPARA 1/4885 |
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | PPARG, PPARA, PPARD | TARBP2 2716/4885PPARG 1/4885PPARA 2/4885 |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARG, PPARD | TARBP2 4382/4885PPARG 2/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.